Author: Extroverting

Read More

Cantheon Provides Funding to Albert Labs for Psilocybin Drug Development

Canadian biopharmaceutical company Albert Labs International Corp. secured a C$830,000 ($621,600) injection from psychedelic pharmaceutical investment firm Cantheon Capital LLC. The investment will support Albert Labs’ forthcoming clinical trials of KRN-101, its primary drug candidate, which is a psilocybin-based natural pharmaceutical product. The company said that the trials are scheduled …